EchoStar Corporation, controlled by billionaire Charlie Ergen, has elected not to make a $326 million cash interest payment due May 30, 2025, on its 10.75% senior spectrum secured notes maturing in 2029. The company cited uncertainty stemming from a Federal Communications Commission (FCC) investigation regarding its compliance with spectrum use terms as the reason for the missed payment. EchoStar has a 30-day grace period to make the payment before it becomes an event of default. The FCC's probe has frozen the company's ability to make decisions, and EchoStar is seeking relief from the regulator. This development has triggered ongoing securities fraud investigations, with multiple law firms encouraging investors who suffered losses to consider class action lawsuits against EchoStar. The situation has drawn attention due to EchoStar's significant investments, including $30 billion in the U.S. and creation of over 12,000 jobs. Separately, UroGen Pharma Ltd. experienced a 45% stock decline following negative regulatory advisory committee votes related to its bladder cancer treatment, prompting shareholder class action lawsuits alleging investor misinformation. Other companies, including DoubleVerify Holdings, Inc., Viatris Inc., Organon & Co., Red Cat Holdings, Inc., and BioSig Technologies, are also facing securities fraud investigations or class action lawsuits.